The legal landscape around psilocybin is shifting faster than at any point since the Controlled Substances Act was passed in 1970. This page summarises the major developments through mid-2025 — always verify current status in your specific jurisdiction, as laws and regulatory frameworks change frequently.
Regulated Therapeutic Access: Oregon and Colorado
Oregon (Measure 109, 2020): Oregon created the first state-regulated psilocybin services framework in the US. Adults 21+ can legally access supervised psilocybin sessions at licensed service centres without requiring a medical diagnosis. Sessions must be conducted on-site by a licensed facilitator. The Oregon Health Authority (OHA) has licensed facilitators and service centres since 2023. This is a therapeutic access model, not recreational legalisation — there is no take-home product.
Colorado (Proposition 122 / Natural Medicine Health Act, 2022): Colorado went further than Oregon by also decriminalising personal possession, use, and home growing of psilocybin for adults 21+, in addition to creating a licensed healing centre framework. The Colorado framework additionally covers DMT, ibogaine, and mescaline from non-peyote sources. The Department of Regulatory Agencies (DORA) oversees licensing; healing centres began opening in 2024.
City-Level Decriminalisation in the United States
A growing number of US cities have decriminalised psilocybin possession (meaning it is de-prioritised for enforcement or civil rather than criminal penalties apply). Major examples include:
- Denver, Colorado (2019): First city to decriminalise psilocybin mushroom possession.
- Oakland and Santa Cruz, California (2019–2020): Decriminalised personal use and possession of all natural psychedelics.
- Washington, DC (Initiative 81, 2020): Made enforcement of personal possession laws for psilocybin and other entheogenic plants the lowest enforcement priority.
- Ann Arbor, Michigan; Somerville, Cambridge, Northampton, Massachusetts; Seattle, Washington; Detroit, Michigan: All have passed decriminalisation resolutions through local councils or referenda.
Decriminalisation does not mean legal sale. Purchasing psilocybin outside a licensed framework (where one exists) remains illegal in all these jurisdictions.
Australia: First Country to Permit Prescription Psilocybin Therapy
In February 2023, the Australian Therapeutic Goods Administration (TGA) rescheduled psilocybin from Schedule 9 (prohibited) to Schedule 8 (controlled), permitting authorised psychiatrists to prescribe psilocybin for treatment-resistant depression (TRD) and MDMA for PTSD. This represented the world's first national regulatory pathway for prescribed psychedelic-assisted therapy. Prescriptions must be approved by a state-authorised psychiatrist and administered in clinical settings; this is not general access.
Canada: Section 56 Exemptions and Special Access
Health Canada has granted Section 56 exemptions under the Controlled Drugs and Substances Act (CDSA) to select terminally ill patients and to therapists for training purposes. The Special Access Programme (SAP) allows licensed practitioners to request psilocybin access for individual patients with life-threatening conditions when conventional treatments have failed. Psilocybin remains Schedule III under the CDSA; these are narrow legal pathways, not general decriminalisation.
United Kingdom: No Access, but Research Leading
Psilocybin is a Class A substance under the Misuse of Drugs Act 1971 and Schedule 1 under the Misuse of Drugs Regulations 2001. There is no approved patient access pathway in the UK. However, a cross-party parliamentary group and organisations including Drug Science have advocated for rescheduling from Schedule 1 to Schedule 2 to facilitate research. COMPASS Pathways (a UK-based company) is conducting large Phase 2b and Phase 3 trials across EU, UK, and US sites. MHRA has granted Innovative Licensing and Access Pathway (ILAP) designations.
Netherlands: Truffle Tolerance
The Netherlands banned psilocybin mushrooms in 2008 but did not schedule psilocybin truffles (sclerotia). Truffles are legally sold in "smart shops" and used in licensed retreat centres. This is a regulatory grey area — psilocybin itself is a controlled substance, but truffles were omitted from the scheduling. The tolerance framework allows an active legal retreat industry.
Global Trend Summary
The overall trend through 2025 has been toward narrowing prohibitions at the therapeutic end (Australia, Canada, Oregon, Colorado) while general possession decriminalisation expands at the city level in the US. International treaties — particularly the UN Convention on Psychotropic Substances (1971) — constrain national governments from outright legalisation without reform. Full national legalisation (outside of Jamaica, where psilocybin is simply unscheduled) remains absent globally.
How to Stay Current
- MAPS (maps.org): Tracks research and policy developments globally.
- Drug Policy Alliance (drugpolicy.org): US-focused policy tracking and advocacy.
- Drug Science (drugscience.org.uk): UK-focused evidence-based policy tracking.
- Chacruna Institute (chacruna.net): Research and policy analysis with cultural context.
- ClinicalTrials.gov / ISRCTN: Track active psilocybin trials by jurisdiction.